目的 探讨生长抑素联合埃索美拉唑治疗98例重症胰腺炎的临床疗效。方法 选取2013年2月-2016年2月我院收治的 98例重症胰腺炎患者为对象，按照入院顺序编号的奇偶性将其均分为研究组和对照组各49例，对照组实施一般治 疗，实验组实施生长抑素联合埃索美拉唑治疗，观察治疗前后两组血清淀粉酶和C反应蛋白(CRP)水平变化，比较 两组临床疗效和药物安全性。结果 治疗前，两组的血清淀粉酶和CRP浓度均无统计学差异(P＞0.05)，治疗后实验 组的血清淀粉酶(126.37±26.51)(U/L)和CRP浓度(114.26±12.48)(mg/L)均低于对照组(172.62±25.14)(U/L)和 (132.30±15.91)(mg/L)，实验组治疗有效率83.67%高于对照组57.14%，差异均有统计学意义(P＜0.05)，两组的药 物安全性相较无统计学差异(P＞0.05)。结论 生长抑素联合埃索美拉唑治疗重症胰腺炎，能通过有效减少胰腺自身 消化和炎症反应的发生从而提高临床疗效，且药物安全性高，值得推广。

Objective To explore the clinical efficacy of somatostatin combined with esomeprazole in the treatment of 98 cases of severe pancreatitis. Methods A total of 98 patients with severe pancreatitis admitted to our hospital from February 2013 to February 2016 were selected for the study. According to the parity of admission order, they were divided into study group and control group, with 49 cases in each group. Control group was given general treatment, and study group was given somatostatin combined with esomeprazole. The changes of serum amylase and C-reactive protein (CRP) were observed before and after treatment. The clinical efficacy and drug safety were compared between the two groups. Results Before treatment, there were no significant differences in serum amylase and CRP concentrations between the two groups (P>0.05). Serum amylase with (126.37±26.51) (U/L) and CRP concentration with (114.26±12.48) (mg/L) in study group after treatment were lower than those in control group with (172.62±25.14) (U/L) and (132.30±15.91) (mg/L). The effective rate of treatment in study group was higher than that of the control group (83.67% vs 57.14%) (P<0.05). There was no significant difference in drug safety between the two groups (P>0.05). Conclusion Somatostatin combined with esomeprazole for severe pancreatitis can improve the clinical efficacy by effectively reducing the pancreas auto digestion and inflammatory reactions, and it has high drug safety, and it is worthy of promotion.